We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression

This study is currently recruiting participants.
Verified December 2015 by Ricardo Alexandre Toniolo, University of Sao Paulo
ClinicalTrials.gov Identifier:
First Posted: August 1, 2012
Last Update Posted: December 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Ricardo Alexandre Toniolo, University of Sao Paulo
The purpose of this study is to determine whether creatine monohydrate is effective as an adjuvant treatment for bipolar depression.

Condition Intervention Phase
Bipolar I Disorder Current Episode Depressed Dietary Supplement: creatine monohydrate Dietary Supplement: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Creatine Monohydrate as Adjunctive Therapy for Bipolar Depression

Resource links provided by NLM:

Further study details as provided by Ricardo Alexandre Toniolo, University of Sao Paulo:

Primary Outcome Measures:
  • MADRS (Montgomery-Asberg depression Rating Scale) [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • HDRS-17 (Hamilton Depression Rating Scale - 17-item version) [ Time Frame: 6 weeks ]

Other Outcome Measures:
  • CGI (Clinical Global Impressions Scale) - Severity and Improvement [ Time Frame: 6 weeks ]
  • YMRS (Young Mania Rating Scale) [ Time Frame: 6 weeks ]

Estimated Enrollment: 44
Study Start Date: July 2012
Estimated Study Completion Date: July 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: creatine monohydrate
6g qd for 6 weeks
Dietary Supplement: creatine monohydrate
Placebo Comparator: placebo
6g qd for 6 weeks
Dietary Supplement: placebo


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Individuals eligible for the study will be adults aged 18 to 60 years of age who met DSM-IV criteria assessed by the SCID (Structural Clinical Interview for DSM-IV) for type I bipolar disorder, current episode depressed.
  • Patients who have scored > 19 on the Montgomery-Asberg Depression Rating Scale (MADRS) will be included, although more than two weeks of treatment with lithium (serum level> 0.8 mEq / L), valproate (serum levels> 50 mg / L) or quetiapine (300-600mg/dia dose) or drug combination.
  • Antipsychotics, anticonvulsants, benzodiazepines, and thyroid supplementation will be allowed if the dose has remained stable over the past two weeks.
  • Antidepressants will be allowed if the dosage has remained stable for 4 weeks.

Exclusion Criteria:

  • Subjects with substance abuse within 2 weeks before inclusion or substance dependence up to 2 months will not be included.
  • Other exclusion criteria will be:

    • diagnosis of schizophrenia,
    • dementia,
    • delirium,
    • epilepsy,
    • mental retardation,
    • clinically unstable medical illnesses,
    • preexisting renal disease,
    • history of hypersensibility to creatine.
  • Not included are individuals at high risk for suicidal or homicidal behavior or self-mutilation will not be included.
  • Women with gestational potential can only be included if they are using reliable contraception.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655030

Contact: Ricardo Toniolo, MD 55 11 26617928 ricardotoniolo.md@gmail.com

Institute of Psychiatry - HC-FMUSP Recruiting
Sao Paulo, SP, Brazil, 01060-970
Sponsors and Collaborators
University of Sao Paulo
Principal Investigator: Beny Lafer, PhD Bipolar Disorder Research Program, Coordinator, IPq-HC-FMUSP
  More Information

Responsible Party: Ricardo Alexandre Toniolo, MD, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT01655030     History of Changes
Other Study ID Numbers: CR-BD-RCT
First Submitted: July 29, 2012
First Posted: August 1, 2012
Last Update Posted: December 2, 2015
Last Verified: December 2015

Additional relevant MeSH terms:
Bipolar Disorder
Behavioral Symptoms
Bipolar and Related Disorders
Mental Disorders